vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and MSCI Inc. (MSCI). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $822.5M, roughly 1.4× MSCI Inc.). MSCI Inc. runs the higher net margin — 34.6% vs -24.1%, a 58.7% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 10.6%). MSCI Inc. produced more free cash flow last quarter ($488.7M vs $46.0M). Over the past eight quarters, MSCI Inc.'s revenue compounded faster (10.0% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
MSCI Inc. is an American finance company headquartered in New York City. MSCI is a global provider of equity, fixed income, real estate indices, multi-asset portfolio analysis tools, ESG and climate finance products. It operates the MSCI World, MSCI Emerging Markets, and MSCI All Country World (ACWI) indices, among others.
ELAN vs MSCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $822.5M |
| Net Profit | $-276.0M | $284.7M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 56.4% |
| Net Margin | -24.1% | 34.6% |
| Revenue YoY | 12.2% | 10.6% |
| Net Profit YoY | -3350.0% | -6.8% |
| EPS (diluted) | $-0.55 | $3.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $822.5M | ||
| Q3 25 | $1.1B | $793.4M | ||
| Q2 25 | $1.2B | $772.7M | ||
| Q1 25 | $1.2B | $745.8M | ||
| Q4 24 | $1.0B | $743.5M | ||
| Q3 24 | $1.0B | $724.7M | ||
| Q2 24 | $1.2B | $707.9M | ||
| Q1 24 | $1.2B | $680.0M |
| Q4 25 | $-276.0M | $284.7M | ||
| Q3 25 | $-34.0M | $325.4M | ||
| Q2 25 | $11.0M | $303.6M | ||
| Q1 25 | $67.0M | $288.6M | ||
| Q4 24 | $-8.0M | $305.5M | ||
| Q3 24 | $364.0M | $280.9M | ||
| Q2 24 | $-50.0M | $266.8M | ||
| Q1 24 | $32.0M | $256.0M |
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — | ||
| Q1 24 | 57.3% | — |
| Q4 25 | -22.6% | 56.4% | ||
| Q3 25 | -4.4% | 56.4% | ||
| Q2 25 | 2.0% | 55.0% | ||
| Q1 25 | 5.0% | 50.6% | ||
| Q4 24 | -5.0% | 54.5% | ||
| Q3 24 | 54.3% | 55.4% | ||
| Q2 24 | -2.7% | 54.0% | ||
| Q1 24 | 1.0% | 49.9% |
| Q4 25 | -24.1% | 34.6% | ||
| Q3 25 | -3.0% | 41.0% | ||
| Q2 25 | 0.9% | 39.3% | ||
| Q1 25 | 5.6% | 38.7% | ||
| Q4 24 | -0.8% | 41.1% | ||
| Q3 24 | 35.3% | 38.8% | ||
| Q2 24 | -4.2% | 37.7% | ||
| Q1 24 | 2.7% | 37.6% |
| Q4 25 | $-0.55 | $3.81 | ||
| Q3 25 | $-0.07 | $4.25 | ||
| Q2 25 | $0.02 | $3.92 | ||
| Q1 25 | $0.13 | $3.71 | ||
| Q4 24 | $-0.01 | $3.89 | ||
| Q3 24 | $0.73 | $3.57 | ||
| Q2 24 | $-0.10 | $3.37 | ||
| Q1 24 | $0.06 | $3.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $515.3M |
| Total DebtLower is stronger | $3.9B | $6.2B |
| Stockholders' EquityBook value | $6.5B | $-2.7B |
| Total Assets | $13.4B | $5.7B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $515.3M | ||
| Q3 25 | $505.0M | $400.1M | ||
| Q2 25 | $539.0M | $347.3M | ||
| Q1 25 | $487.0M | $360.7M | ||
| Q4 24 | $468.0M | $409.4M | ||
| Q3 24 | $490.0M | $501.0M | ||
| Q2 24 | $416.0M | $451.4M | ||
| Q1 24 | $345.0M | $519.3M |
| Q4 25 | $3.9B | $6.2B | ||
| Q3 25 | $4.0B | $5.5B | ||
| Q2 25 | $4.1B | $4.5B | ||
| Q1 25 | $4.4B | $4.5B | ||
| Q4 24 | $4.3B | $4.5B | ||
| Q3 24 | $4.4B | $4.5B | ||
| Q2 24 | $5.7B | $4.5B | ||
| Q1 24 | $5.8B | $4.5B |
| Q4 25 | $6.5B | $-2.7B | ||
| Q3 25 | $6.7B | $-1.9B | ||
| Q2 25 | $6.8B | $-886.2M | ||
| Q1 25 | $6.4B | $-958.6M | ||
| Q4 24 | $6.1B | $-940.0M | ||
| Q3 24 | $6.5B | $-751.0M | ||
| Q2 24 | $5.9B | $-734.5M | ||
| Q1 24 | $6.1B | $-650.5M |
| Q4 25 | $13.4B | $5.7B | ||
| Q3 25 | $13.6B | $5.4B | ||
| Q2 25 | $13.7B | $5.4B | ||
| Q1 25 | $12.9B | $5.3B | ||
| Q4 24 | $12.6B | $5.4B | ||
| Q3 24 | $13.3B | $5.4B | ||
| Q2 24 | $13.8B | $5.5B | ||
| Q1 24 | $14.0B | $5.5B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $501.1M |
| Free Cash FlowOCF − Capex | $46.0M | $488.7M |
| FCF MarginFCF / Revenue | 4.0% | 59.4% |
| Capex IntensityCapex / Revenue | 5.4% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 1.76× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $501.1M | ||
| Q3 25 | $219.0M | $449.4M | ||
| Q2 25 | $237.0M | $336.1M | ||
| Q1 25 | $-4.0M | $301.7M | ||
| Q4 24 | $177.0M | $430.6M | ||
| Q3 24 | $162.0M | $421.6M | ||
| Q2 24 | $200.0M | $349.2M | ||
| Q1 24 | $2.0M | $300.1M |
| Q4 25 | $46.0M | $488.7M | ||
| Q3 25 | $127.0M | $445.5M | ||
| Q2 25 | $180.0M | $324.7M | ||
| Q1 25 | $-69.0M | $290.2M | ||
| Q4 24 | $130.0M | $416.4M | ||
| Q3 24 | $120.0M | $415.0M | ||
| Q2 24 | $166.0M | $340.6M | ||
| Q1 24 | $-22.0M | $295.9M |
| Q4 25 | 4.0% | 59.4% | ||
| Q3 25 | 11.2% | 56.2% | ||
| Q2 25 | 14.5% | 42.0% | ||
| Q1 25 | -5.8% | 38.9% | ||
| Q4 24 | 12.7% | 56.0% | ||
| Q3 24 | 11.7% | 57.3% | ||
| Q2 24 | 14.0% | 48.1% | ||
| Q1 24 | -1.8% | 43.5% |
| Q4 25 | 5.4% | 1.5% | ||
| Q3 25 | 8.1% | 0.5% | ||
| Q2 25 | 4.6% | 1.5% | ||
| Q1 25 | 5.4% | 1.5% | ||
| Q4 24 | 4.6% | 1.9% | ||
| Q3 24 | 4.1% | 0.9% | ||
| Q2 24 | 2.9% | 1.2% | ||
| Q1 24 | 2.0% | 0.6% |
| Q4 25 | — | 1.76× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | 21.55× | 1.11× | ||
| Q1 25 | -0.06× | 1.05× | ||
| Q4 24 | — | 1.41× | ||
| Q3 24 | 0.45× | 1.50× | ||
| Q2 24 | — | 1.31× | ||
| Q1 24 | 0.06× | 1.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
MSCI
| Recurring Subscriptions | $246.4M | 30% |
| Asset Based Fees | $211.7M | 26% |
| Analytics Segment | $182.3M | 22% |
| Sustainability And Climate Segment | $90.3M | 11% |
| Other | $70.9M | 9% |
| Non Recurring | $21.1M | 3% |
